Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

Karo Bio receives US patent for its thyroid hormone receptor platform

The Swedish biotech company Karo Bio today announced that it has expanded and further strengthened the intellectual property portfolio for its thyroid hormone receptor (TR) platform by entering into an agreement that provides Karo Bio with an exclusive license to a US patent from Pfizer Inc.

18 Sep 2009

Drugs industry names the contraceptive pill as the greatest pharmacy innovation of the past 150 years

The Contraceptive Pill has been crowned the greatest pharmacy innovation of the past 150 years, by leading figures in the drugs industry.

18 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation

Dr. Sylvain Meloche, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and his colleagues have uncovered the critical role played by the protein kinase Erk3 in fetal growth potential and lung maturation.

17 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Phthalates & Parabens Profile helps identify exposure levels to chemicals

Personal care products that we use everyday contain chemicals that act as endocrine disruptors, which hinder the normal functions of our hormone systems. Phthalates, also known as plasticizers, are added to plastics to make them flexible to mold into shapes for product packaging and as fragrance for perfumes and air fresheners. Parabens are added to personal care products, such as cosmetics, to extend shelf-life and eliminate fungi and bacteria.

16 Sep 2009

Forest Laboratories places Armour Thyroid medication on back order

Forest Laboratories, Inc., the maker of the widely used hormone therapy drug, Armour® Thyroid, recently announced it has placed the medication on back order. The company said on its website that it does not have enough of the active ingredient, powdered Thyroid gland, in stock to produce the medication.

15 Sep 2009

Pieris AG and Allergan sign collaboration agreement

Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders.

15 Sep 2009

Phase 1 results of CTP-347 presented

Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data on CTP-347, a deuterium-modified analog of paroxetine for the treatment of hot flashes. Concert presented the results during a poster session at the American College of Clinical Pharmacology’s 38th Annual Meeting.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

PTH therapy could prevent osteoarthritis

An existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis, according to an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver.

14 Sep 2009

Body mass in younger and older adulthood linked to prostate cancer risks

A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H.-an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i-has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer. This risk varies among different ethnic groups, according to findings reported in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

14 Sep 2009

High-fat foods can induce binge eating

Findings from a new UT Southwestern Medical Center study suggest that fat from certain foods we eat makes its way to the brain. Once there, the fat molecules cause the brain to send messages to the body's cells, warning them to ignore the appetite-suppressing signals from leptin and insulin, hormones involved in weight regulation.

14 Sep 2009

Weight training may help the elderly retain muscle

Have you ever noticed that people have thinner arms and legs as they get older? As we age it becomes harder to keep our muscles healthy. They get smaller, which decreases strength and increases the likelihood of falls and fractures. New research is showing how this happens — and what to do about it.

11 Sep 2009

Bioidentical hormone therapy is safe and effective for menopausal women

Life Extension(R), the company that long ago sounded the alarm on the dangers of synthetic hormone replacement therapy for menopausal women, has published still more proof that bioidentical hormones offer a far safer treatment option.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Drug manufacturers are seeking out needle-free systems

Many of the novel biopharmaceutical drugs developed now can only be delivered by injection, and this has biologic manufacturers seeking out the most patient-friendly options, including needle-free systems.

11 Sep 2009

Researchers discover the role of endothelin in vaso-occlusive pain

Agonizing physical pain, known as vaso-occlusive pain, can afflict children who have sickle cell disease (SCD). In some cases infants as young as two months of age suffer vaso-occlusive pain so severe that opiate medications and hospitalizations are their only relief. Researchers believe vaso-occlusion is caused by a blockage of the blood vessels that occurs when sickle shaped red cells attempt to pass through the round blood vessels.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009